| |
 |
|
|
Science Forum Index » Medicine - Nutrition Forum » a tentative idea about a possible cancer therapy by stimulat
Page 1 of 1
|
| Author |
Message |
| Guest |
 Posted: Tue Feb 06, 2007 11:11 pm |
|
|
|
|
I have a tentative idea about a possible cancer therapy by stimulation
of sympathetic nerve with a NCP(Neuro Cybernetic Prosthesis).
Here below the basis for this idea are provided,
1.Anticarcinogen N-benzyladriamycin-14-valerate (AD198) can induce
apoptosis by activation of protein kinase C-delta. Many studies in
vivo and in vitro have already proved that N-benzyladriamycin-14-
valerate (AD198) have a better antitumous effect than adriamycin.
£¨1.2.3.4£© Some study showed that N-benzyladriamycin-14-valerate
(AD198) have a weak inhibition effect on topoisomerase II and have a
weak binding to DNA. N-benzyladriamycin-14-valerate (AD198) can
activate PKC-delta following by its binding to deltaC1b domain.£¨5.6.7£©
2.Some studies showed that PKC-a induce the apoptosis following by its
activation of K-Ras.£¨8£©
3.cAMP and its analogues 8--Br--cAMP¡¢8--Cl-cAMP can induced
differentiation of many kinds of cancer cells ,also can suppress
tumor cell growth .£¨9.10.11.12.13.14£©
4.It was reported that nervous tissue are found in tumors.£¨15.16£©
The neurotransmitter noradrenalin releaseed from sympathetic nerve
endings can activate PKC-a and PKC-delta by its interaction with a1
and B receptors, as well as production of cAMP following by activation
of adenylcyclase.
Therefore, it's theoretically possible and feasible to treat cancer
and kill cancer cells by stimulation of sympathetic nerve.
For instance, hepatoma was treated by the stimulation of the
sympathetic nerve which innervated liver by NCP(Neuro Cybernetic
Prosthesis).
reference are as follows,
1¡¢Pharmacology of N-benzyladriamycin-14-valerate in the rat.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10100599&query_hl=1&itool=pubmed_docsum
2¡¢N-benzyladriamycin-14-valerate versus progressively doxorubicin-
resistant murine tumours: cellular pharmacology and characterisation
of cross-resistance in vitro and in vivo.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2605093&query_hl=1&itool=pubmed_DocSum
3¡¢Activity of N-benzyl-adriamycin-14-valerate (AD198), a new
anthracycline derivate, in multidrug resistant human ovarian and
breast carcinoma cell lines.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8845478&query_hl=1&itool=pubmed_docsum
4¡¢N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-
Abl anti-apoptotic signaling in human leukemia cells and also
potentiates imatinib cytotoxicity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17187856&query_hl=1&itool=pubmed_DocSum
5¡¢Molecular models of N-benzyladriamycin-14-valerate (AD 198) in
complex with the phorbol ester-binding C1b domain of protein kinase C-
delta.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11297449&query_hl=1&itool=pubmed_DocSum
6¡¢Interaction of the novel anthracycline antitumor agent N-
benzyladriamycin-14-valerate with the C1-regulatory domain of protein
kinase C: structural requirements, isoform specificity, and
correlation with drug cytotoxicity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12479266&query_hl=1&itool=pubmed_DocSum
7¡¢N-benzyladriamycin-14-valerate (AD198) induces apoptosis through
protein kinase C-delta-induced phosphorylation of phospholipid
scramblase 3.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16267027&query_hl=1&itool=pubmed_DocSum
8¡¢PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes
its association with Bcl-XL on mitochondria and induces apoptosis¡£
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16483930&query_hl=10&itool=pubmed_docsum
9¡¢Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor
growth in vivo.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17234775&query_hl=8&itool=pubmed_docsum
10¡¢Novel reciprocal regulation of cAMP signaling and apoptosis by
orphan G-protein-coupled receptor GPRC5A gene expression.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17055459&query_hl=8&itool=pubmed_DocSum
11¡¢Cyclic AMP inhibition of proliferation of hepatocellular carcinoma
cells is mediated by Akt.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16177565&query_hl=38&itool=pubmed_docsum
12¡¢Rap1 and p38 MAPK mediate 8-chloro-cAMP-induced growth inhibition
in mouse fibroblast DT cells
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16972264&query_hl=30&itool=pubmed_docsum
13¡¢ Cellular sublocalization of Cx43 and the establishment of
functional coupling in IMR-32 neuroblastoma cells.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15605363&query_hl=38&itool=pubmed_docsum
14¡¢Beta-adrenoceptor signaling and its control of cell replication in
MDA-MB-231 human breast cancer cells.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10845278&query_hl=38&itool=pubmed_DocSum
15¡¢Are tumours innervated? Immunohistological investigations using
antibodies against the neuronal marker protein gene product 9.5 (PGP
9.5) in benign, malignant and experimental tumours
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7991987&query_hl=1&itool=pubmed_docsum
16¡¢Tumours may be innervated.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11315618&query_hl=1&itool=pubmed_docsum |
|
|
| Back to top |
|
| |
|
Page 1 of 1
All times are GMT - 5 Hours
The time now is Fri Dec 05, 2008 1:20 am
|
|